This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Tirzepatide reduced HbA1c by 1.24 to 2.58% and body weight by 5.4-11.7 kg.
Why it matters
This medication represents a significant advancement in diabetes treatment, potentially offering better management of blood sugar and weight. Understanding its mechanisms could lead to new therapies for diabetes and obesity.
How the study worked
Five clinical trials (SURPASS 1-5) were conducted with type 2 diabetes patients, comparing tirzepatide to other treatments.
What this study cannot tell us
Further research is needed to fully understand tirzepatide's mechanisms and its long-term effects in humans.
Read the original research
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Cardiovascular diabetology, 21(1), 169
Citation
Nauck, Michael A; D'Alessio, David A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.. Cardiovascular diabetology, 21(1), 169. https://doi.org/10.1186/s12933-022-01604-7